Business News

Caribou Biosciences Receives $25 Million Equity Investment from Pfizer

July 11, 2023

Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Camena Bioscience Raises $10 Million to Pursue DNA Synthesis Technology

July 07, 2023

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene

July 06, 2023

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Donaldson Company Acquires Univercells Technologies for €136 Million

June 30, 2023

Donaldson Company’s €136 million (US$148 million) acquisition of Univercells is designed to broaden its portfolio of biomanufacturing solutions.

Sobi and CTI BioPharma Complete $1.7 Billion Acquisition Deal

June 29, 2023

Sobi has officially acquired CTI, a biopharma company focused on blood related cancers and rare diseases, in a merger valued at approximately $1.7 billion.

Lilly Enters Gene Editing Collaboration with Verve Therapeutics

June 20, 2023

Eli Lilly & Company will pay Verve Therapeutics up to $525 million to advance a lipoprotein gene editing research program.

Advanco Acquires Vantage Consulting Group

June 15, 2023

Advanco’s acquisition of Vantage Consulting Group boosts its position as a provider of independent pharmaceutical serialization solutions.

Pistoia Alliance and Matador Japan Collaborate to Accelerate Research

June 15, 2023

The collaboration between the Pistoia Alliance and Matador Japan will work to accelerate research and promote access to a global pharmaceutical ecosystem.

Mendus and NorthXBiologics Enter Cell Therapy Manufacturing Alliance

June 15, 2023

Mendus and NorthX Biologics will work to develop and commercialize Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine.

AstraZeneca and Quell Therapeutics Strike Cell Therapy Development Deal

June 14, 2023

The deal, valued at more than $2 billion dollars, will see Quell Therapeutics develop various T-regulatory cell therapies for AstraZeneca.